QUAIL-400

About Laguna Biotherapeutics

Laguna Biotherapeutics is pioneering a novel class of in vivo immunotherapies using its proprietary QUAIL Platform, which consists of engineered, highly attenuated microbes. These therapies are designed to activate and expand innate T cells to target difficult-to-treat cancers, including high-risk leukemias and solid tumors, potentially offering a safer and more scalable alternative to complex ex vivo cell therapies. The company is advancing a pipeline of programs for hematologic and solid tumors, positioning itself at the intersection of the microbiome and immuno-oncology fields. As a private, preclinical-stage biotech, Laguna seeks to reimagine cancer treatment by harnessing the evolutionary interplay between microbes and the immune system.

Therapeutic Areas

Other Sarcoma, MSS CRC Drugs